Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly has morphed from a reliable pharma giant into a biotech powerhouse riding blockbuster success. Mounjaro and ...

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for ...

They have been called miraculous and the fastest way to lose weight, but how exactly do these weight loss-drugs work – and ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand access soon.

Kane Biotech Inc. ("Kane Biotech", "Kane" or the "Company") today announces its first quarter 2025 financial results. First Quarter 2025 Financial Highlights (Comparatives Exclude Discontinued STEM ...

Eli Lilly and Company today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

The collaboration will span over 200 Apollo clinics and involve 300 medical practitioners, focusing on patient education, ...

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...